Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company focused on minimally invasive neurostimulation therapy for patients with obstructive sleep apnea. This news page aggregates company announcements, clinical updates, and financial disclosures so readers can follow how Inspire therapy and the Inspire V system are progressing in clinical practice and the marketplace.
Inspire regularly issues earnings releases and financial guidance, including preliminary and unaudited revenue ranges, full-year outlooks, and discussions of non-GAAP measures such as adjusted net income and adjusted EBITDA. Investors can track how revenue tied to Inspire therapy evolves over time, as well as information about share repurchase authorizations and tax-related items disclosed in Form 8-K filings and accompanying press releases.
Because Inspire’s core business is neurostimulation-based treatment for moderate to severe obstructive sleep apnea, a significant portion of its news flow centers on clinical data and product evolution. The company publishes outcomes from studies of the Inspire V system, including procedure success rates, reductions in disease severity, and patient adherence, and presents these results at medical meetings such as the American Academy of Otolaryngology–Head and Neck Surgery and the International Surgical Sleep Society.
Corporate governance and leadership changes are also covered, including announcements about the transition of the Chief Financial Officer role, executive employment agreements, and retirement plans for senior leaders. In addition, Inspire frequently reports on its participation in major healthcare and investor conferences, where management discusses business performance, reimbursement developments, and strategic priorities.
By reviewing this news feed, followers of INSP stock can see how Inspire communicates its financial performance, clinical evidence, regulatory and reimbursement context, and leadership decisions over time, all drawn from company-issued releases and related SEC filings.
Inspire Medical Systems (NYSE:INSP), a medical technology company specializing in obstructive sleep apnea solutions, has announced a $200 million share repurchase program authorized by its Board of Directors. The program will run through August 7, 2027.
The announcement comes following the full U.S. launch of Inspire V, the company's next-generation neurostimulation system, representing their largest product launch to date. CEO Tim Herbert emphasized the company's strong financial position, which enables both capital return to shareholders and continued growth investments.
The company maintains flexibility in executing the buyback through various means, including open market purchases and private transactions, with no obligation for a specific number of shares.
Inspire Medical Systems (NYSE:INSP) reported mixed Q2 2025 financial results, with revenue growing 11% year-over-year to $217.1 million. The company posted a net loss of $3.6 million, or $0.12 per share, compared to net income of $9.8 million in Q2 2024. Adjusted net income was $13.3 million ($0.45 per share).
The company launched its next-generation Inspire V neurostimulation system in the U.S., though the rollout is progressing slower than anticipated. Due to these operational challenges, INSP revised its full-year 2025 guidance downward, now expecting revenue of $900-910 million (previously $940-955 million) and diluted EPS of $0.40-0.50 (down from $2.20-2.30).
Additionally, Randy Ban, Executive VP of Patient Access and Therapy Development, announced his retirement effective January 30, 2026.
Inspire Medical Systems (NYSE: INSP) has scheduled its second quarter 2025 financial results release for August 4, 2025 after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss financial performance and business updates.
Investors can access the earnings call through two methods: a webcast via the company's Investor Relations website for those planning to listen only, or a separate registration link for those intending to ask questions. The company recommends registering at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a pioneer in obstructive sleep apnea medical technology, has announced its upcoming participation in the BofA Securities 2025 Health Care Conference.
The company's management team is scheduled to deliver their presentation on Tuesday, May 13, 2025, at 2:20 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast.
Key Details:
- Event: BofA Securities 2025 Health Care Conference
- Date: May 13, 2025
- Time: 2:20 p.m. ET
- Access: Live webcast available
- Replay: Available for two weeks post-presentation in the Event Archive section of Inspire's Investor website
Inspire Medical Systems (NYSE: INSP) has announced the appointment of two leading physicians as Vice President, Senior Medical Directors. Dr. Paul T. Hoff, an otolaryngologist, and Dr. Ruchir P. Patel, a sleep medicine specialist, will join the company effective April 21 and June 2, respectively.
Dr. Hoff, an Associate Professor at the University of Michigan with over 25 years of clinical practice, has served as President of both the Michigan Otolaryngology Society and International Surgical Sleep Society. Dr. Patel, founder of The Insomnia and Sleep Institute of Arizona, brings 15 years of clinical experience and expertise in sleep disorders medicine.
Both physicians will maintain their independent clinical practices while contributing to Inspire's medical education, training, and future technology developments for obstructive sleep apnea (OSA) treatment solutions.
Inspire Medical Systems (NYSE: INSP) has scheduled its first quarter 2025 financial results release for Monday, May 5, 2025, after market close. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the quarterly results and recent business developments.
The earnings call will be accessible through two options: a webcast via the company's Investor Relations page for listeners, and a separate registration link for participants planning to ask questions. Participants are advised to register at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will be archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its upcoming participation at the KeyBanc Capital Markets Healthcare Forum.
The company's management team is scheduled to deliver their presentation on Tuesday, March 18, 2025, at 3:00 p.m. Eastern Time. Investors and interested parties can access the presentation through a live webcast, with a replay available for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
